Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure

The relation between pretreatment serum sodium concentration and the early and late effects of captopril was examined in 77 consecutive patients with severe chronic heart failure, in whom cardiac catheterization was performed during initiation of treatment and after 2 to 8 weeks. Two groups of patients were defined: 37 patients had hyponatremia (serum sodium less than 135 mEq/liter, group A) and 40 patients had a normal serum sodium concentration (greater than or equal to 135 mEq/liter, group B). With first doses of captopril, patients in group A showed more marked hemodynamic responses than did patients in group B (p less than 0.02). The changes in mean arterial pressure and left ventricular filling pressure seen with first doses of the drug varied linearly and inversely with the pretreatment serum sodium concentration (r = -0.58 and r = -0.53, respectively); this was likely related to the finding that, before administration of captopril, the serum sodium concentration varied linearly and inversely with the logarithm of the plasma renin activity (r = -0.78). However, the pretreatment serum sodium concentration did not predict the long-term hemodynamic or clinical responses to converting enzyme inhibition. Symptomatic hypotension occurred early in the course of therapy (within 24 hours of initiating captopril therapy) in 9 (12%) of the 77 patients; 8 of these 9 had severe hyponatremia (serum sodium less than 130 mEq/liter) and comprised 53% of the 15 patients in our study with such low serum sodium concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				L. Balling, M. Schou, L. Videbaek, P. Hildebrandt, H. Wiggers, F. Gustafsson, and for the Danish Heart Failure Clinics Network Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure Eur J Heart Fail, September 1, 2011; 13(9): 968 - 973. [Abstract] [Full Text] [PDF]

				D. Aronson, J. G. Verbalis, M. Mueller, H. Krum, and on behalf of the DILIPO investigators Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study Eur J Heart Fail, March 1, 2011; 13(3): 327 - 336. [Abstract] [Full Text] [PDF]

				A. A. Mohammed, R. R. J. van Kimmenade, M. Richards, A. Bayes-Genis, Y. Pinto, S. A. Moore, and J. L. Januzzi Jr Hyponatremia, Natriuretic Peptides, and Outcomes in Acutely Decompensated Heart Failure: Results From the International Collaborative of NT-proBNP Study Circ Heart Fail, May 1, 2010; 3(3): 354 - 361. [Abstract] [Full Text] [PDF]

				S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]

				2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]

				L. Klein, C. M. O'Connor, J. D. Leimberger, W. Gattis-Stough, I. L. Pina, G. M. Felker, K. F. Adams Jr, R. M. Califf, M. Gheorghiade, and for the OPTIME-CHF Investigators Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study Circulation, May 17, 2005; 111(19): 2454 - 2460. [Abstract] [Full Text] [PDF]

				C. T.C. Lien, N. D. Gillespie, A. D. Struthers, and M. E.T. McMurdo Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas Eur J Heart Fail, January 1, 2002; 4(1): 91 - 98. [Abstract] [Full Text] [PDF]

				J. R. Oster and B. J. Materson Renal and Electrolyte Complications of Congestive Heart Failure and Effects of Therapy With Angiotensin-Converting Enzyme Inhibitors Arch Intern Med, April 1, 1992; 152(4): 704 - 710. [Abstract] [PDF]

				C. Panciroli, G. Galloni, A. Oddone, E. Marangoni, A. Masa, W. R. Cominesi, V. Caizzi, C. Pezzi, S. Belletti, C. Comalba, et al. Prognostic Value of Hyponatremia in Patients with Severe Chronic Heart Failure Angiology, August 1, 1990; 41(8): 631 - 638. [Abstract] [PDF]